Genetic Ovarian and Breast Cancer Treatments Getting a Fresh Look

“Drug makers are rallying to a class of drugs that, if they succeed, could be the first treatments to target breast and ovarian cancers tied to the genetic mutations known as BRCA 1 and BRCA 2.

Two years ago, the drugs were all but written off after a string of clinical study failures in broader cancer-patient populations. But later research and a closer examination of existing data showed the drugs, known as PARP inhibitors, had a pronounced effect in BRCA patients.”  Read the full article here.